116 related articles for article (PubMed ID: 3279723)
1. Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide. Effect on glycaemic control, serum lipids and lipoproteins.
Laakso M; Sarlund H; Korhonen T; Voutilainen E; Majander H; Hakala P; Uusitupa M; Pyörälä K
Acta Med Scand; 1988; 223(1):61-8. PubMed ID: 3279723
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients.
Laakso M; Rönnemaa T; Sarlund H; Pyörälä K; Kallio V
Diabetes Care; 1989 Feb; 12(2):83-8. PubMed ID: 2649329
[TBL] [Abstract][Full Text] [Related]
3. Association of serum lipids and lipoproteins with plasma C-peptide concentration in non-insulin-dependent diabetic and non-diabetic subjects.
Sarlund H; Laakso M; Pyörälä K; Penttilä I
Metabolism; 1987 Sep; 36(9):840-5. PubMed ID: 3306277
[TBL] [Abstract][Full Text] [Related]
4. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of insulin deficiency among initially non-insulin-dependent middle-aged diabetic individuals.
Laakso M; Sarlund H; Pyörälä K
Diabetes Care; 1986; 9(3):228-31. PubMed ID: 3525053
[TBL] [Abstract][Full Text] [Related]
6. Lipoproteins and apolipoproteins in young nonobese Arab women with NIDDM treated with insulin.
Al-Muhtaseb N; Al-Yusuf AR; Abdella N; Fenech F
Diabetes Care; 1989 May; 12(5):325-31. PubMed ID: 2656141
[TBL] [Abstract][Full Text] [Related]
7. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins.
Vaverková H; Chlup R; Ficker L; Novotny D; Bartek J
Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():74-7. PubMed ID: 9288551
[TBL] [Abstract][Full Text] [Related]
8. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients.
Viikari J; Rönnemaa T; Koskinen P
Ann Clin Res; 1987; 19(3):178-82. PubMed ID: 3314647
[TBL] [Abstract][Full Text] [Related]
10. Basal and postglucagon C-peptide levels in Ethiopians with diabetes.
Siraj ES; Reddy SS; Scherbaum WA; Abdulkadir J; Hammel JP; Faiman C
Diabetes Care; 2002 Mar; 25(3):453-7. PubMed ID: 11874929
[TBL] [Abstract][Full Text] [Related]
11. Inverse relationship of serum HDL and HDL2 cholesterol to C-peptide level in middle-aged insulin-treated diabetics.
Laakso M; Voutilainen E; Sarlund H; Aro A; Pyörälä K; Penttilä I
Metabolism; 1985 Aug; 34(8):715-20. PubMed ID: 3894877
[TBL] [Abstract][Full Text] [Related]
12. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
Wolffenbuttel BH; Weber RF; Weeks L; van Koetsveld PM; Verschoor L
Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
[TBL] [Abstract][Full Text] [Related]
13. Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics.
Laakso M; Voutilainen E; Sarlund H; Aro A; Pyörälä K; Penttilä I
Atherosclerosis; 1985 Sep; 56(3):271-81. PubMed ID: 3902037
[TBL] [Abstract][Full Text] [Related]
14. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Hirano T; Yoshino G; Kashiwazaki K; Adachi M
Am J Hypertens; 2001 Sep; 14(9 Pt 1):908-13. PubMed ID: 11587157
[TBL] [Abstract][Full Text] [Related]
15. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels.
Cavallero E; Dachet C; Neufcour D; Wirquin E; Mathe D; Jacotot B
Metabolism; 1994 Mar; 43(3):270-8. PubMed ID: 8139473
[TBL] [Abstract][Full Text] [Related]
16. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.
Brussaard HE; Gevers Leuven JA; Frölich M; Kluft C; Krans HM
Diabetologia; 1997 Jul; 40(7):843-9. PubMed ID: 9243107
[TBL] [Abstract][Full Text] [Related]
17. Advantageous metabolic effects of pulsatile insulin delivery in noninsulin-dependent diabetic patients.
Paolisso G; Sgambato S; Gentile S; Memoli P; Giugliano D; Varricchio M; D'Onofrio F
J Clin Endocrinol Metab; 1988 Nov; 67(5):1005-10. PubMed ID: 3053747
[TBL] [Abstract][Full Text] [Related]
18. Plasma lipoproteins and apolipoproteins in insulin-dependent and young non-insulin-dependent Arab women.
al-Muhtaseb N; al-Yuosuf AR; Bajaj JS
Acta Diabetol Lat; 1991; 28(1):61-9. PubMed ID: 1862693
[TBL] [Abstract][Full Text] [Related]
19. Restoration of sensitivity to sulfonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects.
Torella R; Salvatore T; Cozzolino D; Giunta R; Quatraro A; Giugliano D
Diabete Metab; 1991; 17(5):443-7. PubMed ID: 1752344
[TBL] [Abstract][Full Text] [Related]
20. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.
Juntti-Berggren L; Pigon J; Karpe F; Hamsten A; Gutniak M; Vignati L; Efendic S
Diabetes Care; 1996 Nov; 19(11):1200-6. PubMed ID: 8908380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
